Search
vadadustat
Indications:
- anemia due to chronic kidney disease
Dosage:
- start 300 mg PO QD, Max 600 mg QD
Mechanism of action:
- prolyl hydroxylase inhibitor
- stabilizes hypoxia-inducible factor
- stimulates erythropoietin & erythrocyte production
General
hematologic agent
enzyme inhibitor
References
- Chertow GM, Pergola PE, Farag YMK
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
N Engl J Med 2021; 384:1589-1600. April 29
PMID: 33913637
https://www.nejm.org/doi/full/10.1056/NEJMoa2035938